<DOC>
	<DOCNO>NCT02884479</DOCNO>
	<brief_summary>The purpose study test PT-112 Combination Docetaxel Subjects Advanced Solid Tumor Phase I Dose Escalation Study Subjects Non-Small Cell Lung Cancer .</brief_summary>
	<brief_title>An Open-Label Phase I/II Clinical Study PT-112 Combination With Docetaxel Subjects With Advanced Solid Tumor Phase I Dose Escalation Study Subjects With Non-Small Cell Lung Cancer ( NSCLC ) Phase II Dose Confirmation Study</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Subjects must meet follow inclusion criterion eligible enrollment study : 1 . Male female ≥ 20 year age day sign informed consent . 2 . Subjects advance tumor histological type meet follow eligibility criterion correspond part study : In Part 1 , subject fail least one prior therapy must pathologically confirm advanced solid tumor histological type preference subject advance NSCLC either available , intolerable , standard ofcare treatment . In Part 2 , subject must pathologically confirm advanced NSCLC . Subjects require evidence measurable disease per RECIST v1.1 . 3 . Eastern Collaborative Oncology Group ( ECOG ) Performance Status ≤ 1 . 4 . Subject must adequate organ function indicate follow laboratory value : Absolute neutrophil count ( ANC ) ≥ 1.5 × 109/L . Platelets ≥ 100 × 109/L . Hemoglobin ≥ 90 g/L 5.6 mmol/L . Serum creatinine ≤ 1.5 × upper limit normal ( ULN ) , calculate directly measure creatinine clearance ≥ 60 % low limit normal ( LLN ) . Serum total bilirubin ≤ 1.5 × ULN ( subject Gilbert 's Syndrome allow direct bilirubin within normal limit ) . Aspartate aminotransferase ( AST [ SGOT ] ) and/or alanine aminotransferase ( ALT [ SGPT ] ) ≤ 2.5 × ULN , ≤ 5 × ULN presence liver metastases . International normalized ratio ( INR ) prothrombin time ( PT ) ≤ 1.5 × ULN . Activated partial thromboplastin time ( aPTT ) ≤ 1.5 × ULN . Albumin ≥ 3 mg/dL . 5 . Female subject eligible enter participate study : Nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) , include female hysterectomy bilateral oophorectomy ( ovariectomy ) bilateral tubal ligation postmenopausal ( total cessation menses ≥ 1 year ) Childbearing potential , negative serum pregnancy test screening ( within 7 day first investigational product administration ) , breast feeding , use adequate contraception study entry throughout study 180 day last investigational product administration . Adequate contraception , use consistently accordance product label instruction physician , define follow : Vasectomized partner sterile prior female subject 's entry sole sexual partner female . Any intrauterine device document failure rate le 1 % per year . Double barrier contraception define condom spermicidal jelly , foam , suppository , film ; diaphragm spermicide ; male condom diaphragm . 6 . Male subject eligible enter participate study vasectomize agree use contraception study treatment period least 180 day last dose study drug . 7 . Willing able provide write informed consent comply requirement study . Subjects meet follow criterion ineligible participation study : 1 . Any cytotoxic chemotherapy within 21 day , prior initiation study drug . 2 . Receipt three prior regimen cytotoxic chemotherapy ( immunotherapy target therapy count line therapy ) . 3 . History hypersensitivity reaction docetaxel polysorbate 80 component . 4 . Presence acute chronic toxicity prior chemotherapy , exception alopecia , resolve Grade 1 , determine National Cancer Institute 's Common Terminology Criteria Adverse Events ( NCICTCAE ) Version 4.03 . 5 . Evidence peripheral neuropathy Grade 2 great within 28 day prior initiation dose . 6 . Symptomatic brain metastasis require active treatment . 7 . Bone marrow reserve , clinical judgment Principal Investigator , adequate participation study . 8 . Known allergy hypersensitivity Ptcontaining agent , know intolerance prior Ptcontaining agent , judgment Principal Investigator , preclude reexposure Ptcontaining agent . 9 . Radiotherapy within 28 day prior baseline and/or receipt radiotherapy &gt; 25 % bone marrow volume . 10 . Major surgery within 28 day prior initiation study drug combination . 11 . Life expectancy &lt; 12 week . 12 . Active clinically unstable bacterial , viral , fungal infection require systemic therapy . 13 . Known human immunodeficiency virus acquire immunodeficiency syndromerelated illness . 14 . Clinically significant hearing impairment , judge Principal Investigator . 15 . Any follow within 3 month prior initiation study drug : uncontrolled congestive heart failure ( New York Heart Association Classification 3 4 , APPENDIX 2 ) , angina , myocardial infarction , cerebrovascular accident , coronary/peripheral artery bypass graft surgery , transient ischemic attack , pulmonary embolism . 16 . Unstable cardiac dysrhythmias persistent prolongation QTc ( Fridericia ) interval &gt; 450 msec male &gt; 470 msec female . 17 . In Part 2 , previous malignancy , except non squamouscell carcinoma skin carcinomainsitu uterine cervix , unless tumor successfully treat curative intent two year prior study entry . 18 . Use investigational agent within 28 day prior screen . 19 . Pregnant lactate female .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>